The regulatory landscape for assessing the proarrhythmic risk during drug development is changing. The recent update considers an integrated approach of the ICH14 and S7B guidances. Under certain conditions, this brings new insights for the industry, offering the use of non-clinical data during clinical development to overcome the limitations when a high clinical exposure scenario cannot be assessed.